ancreatic cancer, with an overall five-year survival rate ranging from 0.4 percent 1 to 4 percent, 2 has a poor prognosis and is one of the top 10 causes of death from cancer in the Western world. 3, 4 Surgical resection improves the outlook, although only about 10 percent of patients with pancreatic cancer are eligible for the procedure. [5] [6] [7] [8] [9] Most treatment failures are due to local recurrence, hepatic metastases, or both and occur within one to two years after surgery. [10] [11] [12] Adjuvant (postoperative) therapy may improve long-term survival, [7] [8] [9] [13] [14] [15] [16] but its routine use is not universal 8 because the results of randomized trials have been inconclusive. 13 The Gastrointestinal Tumor Study Group (GITSG) randomly assigned 43 patients to receive surgery alone or chemoradiotherapy followed by maintenance chemotherapy. 14, 15 The median survival was significantly longer in the adjuvant-treatment group than in the surgery group (20 months vs. 11 months), with 5-year survival estimates of 18 percent and 8 percent, respectively. 14, 15 Three subsequent randomized studies, however, failed to confirm the benefit of adjuvant treatment. [17] [18] [19] Moreover, it is unclear whether the survival advantage in the GITSG trial was due to the combination of chemoradiotherapy and maintenance chemotherapy or to only one of these treatments. 13 The European Study Group for Pancreatic Cancer (ESPAC) undertook a large, multicenter trial to investigate the possible benefits of adjuvant chemoradiotherapy and maintenance chemotherapy in patients with pancreatic cancer. Although preliminary data indicated a survival benefit for adjuvant chemotherapy, the results were inconclusive owing to the short follow-up of only 10 months. 20, 21 In this report we summarize the results of this trial after it reached the primary end point and a median followup of 47 months among surviving patients. 20, 21 patients and trial design
The ESPAC-1 trial used a two-by-two factorial design in which, after resection of the pancreatic ductal adenocarcinoma, each patient was randomly assigned to receive chemoradiotherapy or chemotherapy, neither treatment, or both treatments (Fig. 1) . The goal was to enroll 70 patients in each of the four groups, yielding combined data for 140 patients in each group for the two main treatment comparisons (chemoradiotherapy vs. no chemoradiotherapy and chemotherapy vs. no chemotherapy) and giving the study the ability to detect absolute differences in the mortality rate at two years of more than 20 percent at a significance level of 5 percent with 90 percent power. The trial was approved by the ethics committees at the national and local level according to the requirements of each country, and all participants gave written informed consent.
Patients who had undergone a complete macroscopic resection 22 of histologically proven pancreatic ductal adenocarcinoma underwent randomization with the use of a blocked method. They were stratified according to the randomization center (the United Kingdom, Switzerland, Germany, or France) and the status of the resection margin (positive or negative). Patients were followed up at three-month intervals until death. A subgroup of patients completed questionnaires about their quality of life. 23 
adjuvant therapy
Chemoradiotherapy consisted of a 20-Gy dose to the tumor given in 10 daily fractions over a two-week period plus an intravenous bolus of fluorouracil (500 mg per square meter of body-surface area on each of the first three days of radiotherapy and again after a planned break of two weeks). Chemotherapy consisted of an intravenous bolus of leucovorin (20 mg per square meter), followed by an intravenous bolus of fluorouracil (425 mg per square meter) on each of 5 consecutive days every 28 days for six cycles. Combination therapy consisted of chemoradiotherapy followed by chemotherapy, both administered as described above.
Adverse effects were assessed with the use of the Common Toxicity Criteria 24 and a clearly defined protocol for modifications and delays of treatment. The study required each center to treat patients according to its own quality-assurance standards for radiotherapy.
statistical analysis
The primary outcome measure was the two-year survival rate; secondary outcomes were the incidence of adverse effects and recurrence and measures of the quality of life. Survival was calculated from the date of resection until the date of death from any cause; for patients lost to follow-up, data were censored on the date the patient was last seen alive. Survival estimates were derived by the method of Kaplan and Meier, 25 and the log-rank test 26 was used to assess differences in survival estimates among the groups. Stratified log-rank analyses and Cox pro- A total of 145 patients were assigned to receive chemoradiotherapy (alone or with adjuvant chemotherapy), and 144 were assigned not to receive chemoradiotherapy -they received chemotherapy alone or were observed -according to the two-bytwo design (Fig. 1) . Treatment details were available for 128 of the 145 patients who received chemoradiotherapy (88 percent), of whom 90 (70 percent) received a total of 40 Gy according to the protocol, 27 (21 percent) received either more or less than 40 Gy, and 11 (9 percent) did not receive any chemoradiotherapy; most protocol violations were due to the patient's decision not to receive the randomly assigned treatment (50 percent) or to progressive disease (19 percent) . A total of 147 patients were assigned to chemotherapy (75 to chemotherapy alone and 72 to chemotherapy in combination with chemoradiotherapy), and 142 did not receive chemotherapy alone (69 were assigned to the observation group and 73 to the chemoradiotherapy group), according to the twoby-two design ( Fig. 1) . Treatment details were available for 122 of the 147 patients randomly assigned to receive chemotherapy (83 percent), of whom 61 (50 percent) received six cycles according to the protocol, 40 (33 percent) received fewer than six cycles, and 21 (17 percent) did not receive any chemotherapy; most protocol violations in this block were due to the patient's decision not to receive chemotherapy (33 percent) or to progressive disease (38 percent). Patients with a protocol violation were included in the analysis in their randomly assigned treatment group on an intention-to-treat basis.
Clinicians were asked to record the most severe episode of myelotoxic effects, stomatitis, diarrhea, and other adverse events. Adverse events of grade 3 or 4 were reported in 29 patients: 7 had hematologic events (2 patients assigned to chemotherapy alone and 5 to combination therapy), 9 had stomatitis (4 patients assigned to chemotherapy alone and 5 to combination treatment), 6 had diarrhea (2 patients assigned to chemotherapy alone and 4 to combination treatment), and 7 had other types of adverse events (2 patients assigned to chemoradiotherapy alone, 3 to chemotherapy alone, and 2 to combination treatment). 
survival
The analysis of survival was based on 237 deaths among the 289 patients (82 percent). The duration of follow-up was similar among the groups; the median was 47 months (interquartile range, 33 to 62)
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Chemotherapy
The median survival was 20. (Fig. 2B) . The Forrest plot (Fig. 4) confirmed a significant survival benefit for chemotherapy whether or not patients were also randomly assigned to receive chemoradiotherapy.
Additional Survival Analyses
The median survival was 16.9 months (95 percent confidence interval, 12.3 to 24.8) among the 69 patients randomly assigned to observation, 13.9 months (95 percent confidence interval, 12.2 to 17.3) among the 73 patients randomly assigned to chemoradiotherapy, 21.6 months (95 percent confidence interval, 13.5 to 27.3) among the 75 patients randomly assigned to chemotherapy, and 19.9 months (95 percent confidence interval, 14.2 to 22.5) among the 72 patients randomly assigned to chemoradiotherapy plus chemotherapy. The respective five-year survival estimates were 11 percent, 7 percent, 29 percent, and 13 percent. This two-bytwo trial did not have the statistical power to compare these four groups directly.
Influence of Prognostic Factors
Log-rank analysis of the characteristics of patients and tumors revealed no significant differences in survival with respect to sex; an age of 60 years or more, as compared with less than 60 years; and the presence of preoperative diabetes, local invasion at operation, and postoperative complications, but borderline effects were found for current smoking (P=0.07), positive resection margins (P=0.10), and the presence of involved adjacent structures on histologic analysis (P=0.10). Increasingly differentiated tumors (P<0.001), the presence of lymph-node involvement (P<0.001), and a maximal tumor size of more than 2 cm, as compared with 2 cm or less (P=0.003), had significant adverse influences on survival. Stratifying treatment effects according to each of these factors did not influence the overall treatment result. Cox regression modeling identified the grade of disease, tumor size (retained as a continuous variable), and lymph-node status as independent prognostic factors, adjusted for two stratification factors at randomization: randomization center (United Kingdom, Switzerland, Germany, or France) and resection-margin status (negative or positive) ( Table  2 ). The analysis confirmed an adjusted hazard ratio for death of 1.47 (95 percent confidence interval, 1.10 to 1.95) with the use of chemoradiotherapy and an adjusted hazard ratio for death of 0.77 (95 percent confidence interval, 0.58 to 1.01) with the use of chemotherapy ( Table 2 ). The interaction between chemotherapy and chemoradiotherapy in patients who underwent randomization according to the two-by-two design was tested with the use of a formal log-rank test and a multiplication interaction term, and the results of both were nonsignificant.
recurrence
Of 158 patients who were known to have had a tumor recurrence, local recurrence alone was reported in 56 (35 percent), distant metastases alone in 53 (34 percent), and both types in 43 (27 percent) ; the site of recurrence was unknown in 6 patients (4 percent). Known recurrences were identified in 84 of 102 patients who were assigned to chemoradiotherapy (82 percent) and in 74 of 106 patients who did not receive chemoradiotherapy (70 percent 
quality of life
Questionnaires regarding the quality of life were completed by 152 of the 289 patients (53 percent), a representative sample of the main study group. There were no significant differences in the mean observed quality of life within 12 months after resection between patients who received chemotherapy and those who did not receive chemotherapy (P=0.75) or between patients who received chemoradiotherapy and those who did not receive chemoradiotherapy (P=0.17).
The results of the ESPAC-1 trial, which was a large, adequately powered, randomized trial of adjuvant treatment for resectable pancreatic cancer, show a significant survival benefit for adjuvant chemotherapy. The effect of adjuvant chemotherapy is particularly encouraging, since 18 percent of the patients had positive resection margins, a criterion for exclusion in the GITSG trial. 14, 15 Our results also show that adjuvant chemoradiotherapy not only fails to benefit patients but also reduces survival when it is given before chemotherapy. The European Organization for Research and Treatment of Cancer (EORTC) randomly assigned 218 patients with pancreatic or ampullary tumors to adjuvant chemoradiotherapy (but no maintenance chemotherapy) or surgery alone. 17 There was no significant difference in survival between the groups, including the 114 patients with pancreatic cancer, with median survivals of 17 and 13 months in the treatment and observation groups, respectively, and with 5-year survival estimates of 23 percent and 10 percent, respectively. 17 Even apart from the high dropout rate, however, the study was statistically underpowered. A Norwegian study randomly assigned 61 patients (14 with ampullary tumors) to adjuvant chemotherapy (doxorubicin, mitomycin, and fluorouracil) or surgery alone. 18 The median survival was significantly longer in the adjuvant-treatment group than in the observation group (23 months vs. 11 months), but the 5-year survival rate was not (4 percent vs. 8 percent) . 18 This trial was also statistically underpowered, and the results discouraged further use of the doxorubicin-containing regimen because of its toxicity. 18 A Japanese trial reported no benefit from adjuvant chemotherapy, but its design precluded definitive conclusions from being drawn. 19 Evidence that adjuvant chemoradiotherapy for pancreatic cancer improves local control is inconclusive, [30] [31] [32] and better local control has not been shown to correlate with increased survival. 14, 15, 17, 33, 34 In our trial, the rates of local recurrence were not significantly different between patients who received chemoradiotherapy and those who did not receive chemoradiotherapy. Similar findings were reported in the EORTC trial. 17 An analysis of 100,313 U.S. patients with pancreatic cancer in the National Cancer Database revealed that 9044 patients (9 percent) had undergone a pancreatectomy. 8 Of these 9044 patients, only 39.9 percent had received adjuvant treatment: 6.5 percent had received radiotherapy, 5.1 percent chemotherapy, and 28.3 percent a combination of the two. 8 The five-year survival rates were 23.3 percent after resection alone, 13.0 percent in the adjuvant-radiotherapy group, 17.4 percent in the adjuvant-chemotherapy group, and 17.0 percent in the combination-therapy group. 8 Given such results, it is not surprising that there has been uncertainty regarding the use of adjuvant treatment for pancreatic cancer.
The survival curves in our trial began to separate in favor of adjuvant chemotherapy at 8 months after resection, but the curves showing the disadvantage of chemoradiotherapy did not begin to separate until 14 months. The simplest explanation for these observations is that chemoradiotherapy delayed the administration of chemotherapy (which in our trial resulted in a delay in both local and distant recurrences) and consequently reduced the potential benefit of chemotherapy that is derived from delivering it as soon as possible after resection. We conclude that standard care for patients with resectable pancreatic cancer should consist of curative surgery followed by adjuvant systemic chemotherapy.
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